Exploring the Influence of Clinical Factors on the Prognosis of Papillary Renal Cell Carcinoma

Exploring the Influence of Clinical Factors on the Prognosis of Papillary Renal Cell

Patients with renal cell carcinoma who were admitted to the First Affiliated Hospital of Sun Yat-sen University from February 1, 2021, to February 1, 2022, and met the following inclusion and exclusion criteria were collected. Clinical factors influencing the prognosis of enrolled patients were retrospectively analyzed, and a predictive system was established based on this.

(Inclusion criteria: pathology of the surgical specimen confirmed the diagnosis of pRCC,b: age 18 years or older, c: localized RCC underwent radical nephrectomy or partial nephrectomy in our center.

Exclusion criteria:a: lack of original CT images, b: patients with malignant tumors of other systems, c: patients who lost follow-up.)

Study Overview

• Status: Completed
• Conditions: Carcinoma, Renal Cell
• Intervention / Treatment: Other: We do not have any interventions. This study is based on obseravation.

• Study Type: Observational
• Enrollment (Actual): 160

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

• Sampling Method: Non-Probability Sample

Study Population

All the enrolled patients were Asian(we are a affiliated hospital of a university based in Mailand china ).

Description

Inclusion Criteria:

a: pathology of the surgical specimen confirmed the diagnosis of pRCC,b: age 18 years or older, c: localized RCC underwent radical nephrectomy or partial nephrectomy in our center

Exclusion Criteria:

a: lack of original CT images, b: patients with malignant tumors of other systems, c: patients who lost follow-up

Study Plan

How is the study designed?

Number of groups / cohorts

2

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
Patients with tumor progression or recurrence; Patients enrolled in our retrospective study with tumor progression or recurrence	Other: We do not have any interventions. This study is based on obseravation.; observational retrospective study without any interventions
Patients without tumor progression or recurrence; Patients enrolled in our retrospective study without tumor progression or recurrence	Other: We do not have any interventions. This study is based on obseravation.; observational retrospective study without any interventions

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Tumor progression	medical imaging examinations showed tumor progression	12 months

Collaborators and Investigators

• Sponsor: Sun Yat-sen University
• Investigators: Principal Investigator: Wenhui Su, Bachelor, First affiliated hospital, Sun Yat-sen univeristy

Study record dates

Study Major Dates

• Study Start (Actual): February 1, 2012
• Primary Completion (Actual): February 1, 2022
• Study Completion (Actual): February 1, 2022

Study Registration Dates

• First Submitted: October 27, 2023
• First Submitted That Met QC Criteria: October 27, 2023
• First Posted (Actual): November 1, 2023

Study Record Updates

• Last Update Posted (Actual): November 1, 2023
• Last Update Submitted That Met QC Criteria: October 27, 2023
• Last Verified: October 1, 2023

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Neoplasms by Histologic Type; Neoplasms; Urologic Neoplasms; Urogenital Neoplasms; Neoplasms by Site; Kidney Diseases; Urologic Diseases; Adenocarcinoma; Neoplasms, Glandular and Epithelial; Kidney Neoplasms; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Male Urogenital Diseases; Carcinoma, Renal Cell; Carcinoma
• Other Study ID Numbers: IIT-2023-282

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No